Novogen Goodwill and Intangible Assets 2010-2023 | KZIA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Novogen goodwill and intangible assets from 2010 to 2023. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Novogen goodwill and intangible assets from 2010 to 2023. Goodwill and intangible assets can be defined as the sum of all intangible asset fields

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$158.3B
Bristol Myers Squibb (BMY)	$119.4B
Vertex Pharmaceuticals (VRTX)	$116.1B
Gilead Sciences (GILD)	$112.4B
CSL (CSLLY)	$87.2B
Regeneron Pharmaceuticals (REGN)	$81.1B
GSK (GSK)	$70.4B
Argenex SE (ARGX)	$36.6B
Alnylam Pharmaceuticals (ALNY)	$31.6B
BioNTech SE (BNTX)	$27.1B
Biogen (BIIB)	$23B
Illumina (ILMN)	$22.2B
BeiGene (BGNE)	$18.6B
Moderna (MRNA)	$15.8B
Incyte (INCY)	$13.8B
Genmab (GMAB)	$13.7B
Insmed (INSM)	$13.1B
BioMarin Pharmaceutical (BMRN)	$12.2B
Bio-Techne Corp (TECH)	$11.3B
Vaxcyte (PCVX)	$11B
Sarepta Therapeutics (SRPT)	$10.9B
Exelixis (EXEL)	$10.2B
Exact Sciences (EXAS)	$9.8B
QIAGEN (QGEN)	$9.8B
Revolution Medicines (RVMD)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$9.1B
Intra-Cellular Therapies (ITCI)	$9.1B
Repligen (RGEN)	$8B
Ascendis Pharma (ASND)	$7.9B